  |
Full Text (PDF) |
|
| The 13th International Rheumatology Symposium in Okayama April 15 17, 2004, Okayama, Japan |
Hajime Inoue
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| I: Synovial Pathology in Joint Destruction
I-1: Synovial-fibroblast mediated joint destruction |
Steffen Gay1 , Michel Neidhart1, Diego Kyburz1, Mathias Pierer1, Mariola Kurowska-Stolarska1, Oliver Distler1, Thomas Pap1, Ulf Mueller-Ladner1 and Renate E. Gay1
(2) WHO Center for Molecular Biology and Novel Therapeutic Strategies for the Treatment of Rheumatic Diseases, Department of Rheumatology, University Hospital, Gloriastrasse 25, CH-8091 Zurich, Switzerland
Without Abstract
Modern Rheumatology
Japan College of Rheumatology
|
| I: Synovial Pathology in Joint Destruction
I-2: Molecular mechanism of chondrogenesis via chromatin modifications |
Hiroshi Asahara2
(2) The Scripps Research Institute / JST PRESTO, USA
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
I: Synovial Pathology in Joint Destruction
I-3: BiP, the endoplasmic reticulum chaperone, as an immunomodulatory autoantigen in rheumatoid arthritis
|
Gabriel S. Panayi3
(3) Guy's, King's and St. Thomas' School of Medicine, King's College London, Honorary Consultant in Rheumatology, Guy's & St. Thomas' Hospital, London, UK
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| I: Synovial Pathology in Joint Destruction
I-4: Proteomic surveillance of autoimmunity in osteoarthritis |
Tomohiro Kato4
Department of Bioregulation, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| I: Synovial Pathology in Joint Destruction
I-5: Synoviolin, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy |
Toshihiro Nakajima5
(5) Department of Genome Science, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| II: Pros and Cons in Anti-cytokine Therapy for RA
II-1: Anti-TNF therapy: pros and cons |
Marc Feldmann6
(6) Kennedy Institute of Rheumatology Division, Imperial College London, UK
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
II: Pros and Cons in Anti-cytokine Therapy for RA
II-2: The pros and cons of cytokine inhibition for RA
|
David E. Yocum7
(7) Arizona Arthritis Center University of Arizona College of Medicine, Tucson, AZ, USA
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| II: Pros and Cons in Anti-cytokine Therapy for RA
II-3: Pros and cons of anti-TNF therapy for RA |
Roy M. Fleischmann8
(8) University of Texas Southwestern Medical Center at Dallas, USA
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| II: Pros and Cons in Anti-cytokine Therapy for RA
II-4: A closer look on joint destruction |
Josef S. Smolen9
(9) Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
II: Pros and Cons in Anti-cytokine Therapy for RA
II-5: Effect of conventional DMARDs and anti-cytokine therapy on radiographs in RA: What did we learn?
|
Desiree van der Heijde10
(10) University Maastricht, The Netherlands
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
II: Pros and Cons in Anti-cytokine Therapy for RA
II-6: Do we need new treatment principles for RA patients beyond anti-TNF medication?
|
Joachim Kalden11
(11) Department of Internal Medicine III, Institute for Clinical Immunology University of Erlangen-Nuremberg, Germany
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| III: New Frontier Drug Therapy for OA
III-1: Identification of susceptibility gene(s) for osteoarthritis
|
Shiro Ikegawa12
(12) Laboratory for Bone and Joint Diseases, SNP Research
Center, RIKEN, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| III: New Frontier Drug Therapy for OA
III-2: COX-2 regulation in synoviocytes of patients from rheumatoid arthritis |
Hajime Sano13
(13) Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| III: New Frontier Drug Therapy for OA
III-3: Glucosamine sulfate as a structure-modifying agent in osteoarthritis |
Roy D. Altman14
(14) University of California at Los Angeles, Los Angeles, California, USA
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
III: New Frontier Drug Therapy for OA
III-4: Disease modification in osteoarthritis: What is the goal and what is the evidence?
|
Stefan Lohmander15
(15) Department of Orthopaedics, Lund University Hospital, Lund University, SE-22185 Lund, Sweden
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| III: New Frontier Drug Therapy for OA
III-5: The role of cleavage of type II collagen by collagenases in cartilage destruction in osteoarthritis |
Toshihisa Kojima16
(16) Department of Orthopedic Surgery, Nagoya University, School of Medicine, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| IV: Up-to-date Indications in Rheuma-Surgery
IV-1: Locking compression plating (LCP): a new solution for fractures in rheumatoid patients |
Cong-Feng Luo17
(17) Department of Orthopaedic Surgery, Shanghai JiaoTong University Sixth People's Hospital, 600 YiShan Road, Shanghai, 200233, China
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
IV: Up-to-date Indications in Rheuma-Surgery
IV-2: Simultaneous bilateral total knee replacement for patients with rheumatoid arthritis
|
Junnosuke Ryu18 , Shu Saito18 and Takao Ishii18
(18) Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| IV: Up-to-date Indications in Rheuma-Surgery
IV-3: Indication of mobile-type total knee arthroplasty for rheumatoid arthritis |
Hiroshi Tsumura19
(19) Department of Orthopaedic Surgery, Oita University, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| IV: Up-to-date Indications in Rheuma-Surgery
IV-4: Orthopedic surgery in rheumatoid arthritis |
Seppo Santavirta20
(20) Department of Orthopaedic Surgery and Traumatology, Helsinki University Central Hospital, Helsinki, Finland
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| IV: Up-to-date Indications in Rheuma-Surgery
IV-5: Current surgical indication for ulnar drift in the rheumatoid patient |
Yoshitaka Minamikawa21 and Tsukasa Matsubara21
(21) Matsubara Mayflower Hospital, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
V: Regulation of Osteoporosis in Rheumatic Diseases
V-1: Osteoclast formation and bone loss in rheumatoid arthritis (RA)
|
David M. Findlay22, David R. Haynes23, Gerald J. Atkins22, Andrew C.W. Zannettino24, Tania N. Crotti23 and Kencana Dharmapatni23
(22) Departments of Orthopaedics and Trauma, University of Adelaide, Adelaide, South Australia, Australia
(23) Department of Pathology, University of Adelaide, Adelaide, South Australia, Australia
(24) Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Without Abstract
Modern Rheumatology
Japan College of Rheumatology
|
| V: Regulation of Osteoporosis in Rheumatic Diseases
V-2: Mechanisms of bone destruction in experimental arthritis |
Wim B. van den Berg25 and Erik Lubberts25
(25) Rheumatology Research and Advanced Therapeutics, University Medical Center, Nijmegen, The Netherlands
Without Abstract
Modern Rheumatology
Japan College of Rheumatology
|
| V: Regulation of Osteoporosis in Rheumatic Diseases
V-3: Pro-inflammatory cytokines and osteoporosis in rheumatoid arthritis |
Yosuke Fujikawa26
(26) Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
V: Regulation of Osteoporosis in Rheumatic Diseases
V-4: Regulation of synovial fibroblast function by adenovirus vector-mediated gene transduction
|
Sakae Tanaka27 , Aiichiro Yamamoto27, Hiroaki Seto28, Hisashi Kurosawa28, Hiromi Oda27 and Kozo Nakamura27
(27) Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Japan
(28) Department of Orthopaedics, Juntendo University, School
of Medicine, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
V: Regulation of Osteoporosis in Rheumatic Diseases
V-5: The coupling mechanism of bone resorption and formation
|
Nobuyuki Udagawa29
(29) Department of Biochemistry, Matsumoto Dental University, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
V: Regulation of Osteoporosis in Rheumatic Diseases
V-6: Isolation and characterization of osteoclast precursor cells from rheumatoid arthritis synovial fluid: two-step differentiation induced by nurse-like stromal cells and cytokines
|
Tomoko Maeda30
(30) Clinical Research Center for Rheumatology, National Sagamihara Hospital, Japan
Without Abstract
Modern Rheumatology
Japan College of Rheumatology |
| V: Regulation of Osteoporosis in Rheumatic Diseases
V-7: Role of signal transduction pathways in joint destruction |
Gary S. Firestein31
(31) Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, USA
Without Abstract
|
 |
